First Patient Dosed in ATL1102 Phase IIb Duchenne Muscular Dystrophy (DMD) Trial - mailchi.mp/4e7cf19027c8/f…

First Patient Dosed in ATL1102 Phase IIb Duchenne Muscular Dystrophy (DMD) Trial - mailchi.mp/d51f9e289c44/f…

First Patient Dosed in ATL1102 Phase IIb Duchenne Muscular Dystrophy (DMD) Trial - mailchi.mp/7ed293e2ab1b/f…

First Patient Dosed in ATL1102 Phase IIb Duchenne Muscular Dystrophy (DMD) Trial - mailchi.mp/87a5daa5f4b2/f…

MHRA Approval Received to Conduct Phase IIb Trial in the UK for ATL1102 in DMD Key Highlights: Regulatory approvals in all four countries (UK, Turkey, Bulgaria and Australia) to conduct the Phase IIb trial. Three patients have now received a first dose. antisense.com.au/wp-content/upl…

Antisense Therapeutics Limited will be attending the 9th Annual Parent Project Muscular Dystrophy conference in Dallas, Texas USA. Dr Gil Price will present clinical data on ATL1102 and the recently initiated Phase IIb clinical trial. #Duchenne #MuscularDystrophy #PPMDConference

Positive new DMD Combination Therapy Data in mdx mice - mailchi.mp/54a28f05a098/p…

This #WDAD2023 Antisense Therapeutics stands alongside Jett Foundation in solidarity with families affected by Duchenne muscular dystrophy.

Percheron has reported strong progress in the development HMBD-002, including completion of technology transfer, initiation of Phase II manufacturing and team expansion. Join our webinar at 9am on October 7 for Phase I results: bit.ly/4nzjA4W $PER #oncology #biotech #ASX

Final Phase I data for HMBD-002 show a strong safety profile and preliminary evidence of activity across multiple advanced cancers. These results will inform a planned Phase II trial in 2026. Read the ASX release: bit.ly/47dE8Kk  $PER #biotech #ASX

WEBINAR REPLAY | In case you missed it, CEO Dr James Garner presents final Phase I results for HMBD-002 confirming an excellent safety profile and early signs of benefit in advanced cancers. Watch it here: bit.ly/46SRmuE $PER #PercheronTx #oncology #clinicaltrials

$PER CEO Dr James Garner joined investors at Caulfield Racecourse yesterday to discuss the realities of early-stage cancer drug development - and the opportunity ahead for Percheron. #PercheronTx #oncology #immunotherapy #cancerresearch #clinicaltrials

Join Percheron CEO Dr James Garner for the TechKnow Invest Webinar on Tue 18 Nov (9 am AWST / 12 pm AEDT) to hear an update on HMBD-002 and plans to advance into Phase II in 2026. Register here: bit.ly/4reCQab $PER #Percheron #ASX #TechKnowInvest #lifesciences #biotech

Cancers often progress because tumours find ways to switch off the immune system. VISTA, a checkpoint linked to poorer outcomes and resistance to current immunotherapies, is emerging as a key target. With HMBD-002 moving toward Phase II, $PER is advancing this next-gen approach.

Checkpoint inhibitors transformed cancer care, but many patients develop resistance as tumours suppress immunity via VISTA. By targeting this early “off switch,” HMBD-002 aims to unlock immune response sooner and address treatment resistance.

Percheron has released its Quarterly Activities Report, highlighting the Company’s continuing progress during the quarter ended 31 December 2025. Read the ASX release: bit.ly/3ZceJvP $PER #Percheron #oncology #VISTA #pharma #innovation #drugdevelopment #ASX

Percheron Therapeutics Limited CEO and Managing Director Dr James Garner recently spoke with The Stock Network’s Lel Smits about clinical progress and the path into Phase II. Take a look: youtu.be/63HZrwGCl0k?si… $PER #biotech #lifesciences #oncology #innovation

Percheron Therapeutics was pleased to present at the Life Science Investor Day, part of Emergence 2026 in Sydney this week, with CEO Dr James Garner outlining the Company’s clinical roadmap and development progress. #PercheronTherapeutics #ImmunoOncology #Biotech #Emergence2026

Percheron Therapeutics has been featured in the Stockhead Biotech Investor Guide, published in The Australian. The profile outlines the Company’s pivot into immuno-oncology and its acquisition of the phase II-ready HMBD-002 program targeting VISTA. bit.ly/3Or1rJX

Percheron CEO Dr James Garner presented at the Life Science Investor Day at Emergence 2026 in Sydney recently, outlining the Company’s clinical strategy and development trajectory for HMBD-002. Watch the replay: youtu.be/LMweuu-WyD0 $PER #Biotech #LifeSciences